Abstract. Accumulating evidence indicates that Nanog plays a central role in modulating the biological behaviors of human hepatocellular carcinoma (HCC). However, the underlying mechanisms remain unclear. In the present study, we employed transcription activator-like effector nucleases (TALEN) to disrupt Nanog expression in HepG2 cells and obtained subcloned cells with diallelic Nanog mutations. Significantly, we found that the expression of pluripotency factors Sox2, Oct4 and Klf4, as well as expression of cancer stem cell (CSC) marker CD133, in the Nanog-targeted HepG2 cells was markedly downregulated. This finding suggests that Nanog may play an important role in maintaining the pluripotency and malignancy of HepG2 cells. We also revealed that Nanog regulated cell proliferation by modulating the expression of cyclin D1/D3/E1 and CDK2, respectively. Additionally, the disruption of Nanog resulted in the downregulation of epithelial-mesenchymal transition (EMT) regulators Snail and Twist, which contributed to the elevated level of epithelial marker E-cadherin, and to the decreased level of mesenchymal markers N-cadherin and vimentin in the HepG2 cells. In addition, the Nanog-targeted HepG2 cells exhibited reduced ability of invasion, migration and chemoresistance in vitro. In conclusion, the disruption of Nanog expression results in less proliferation, invasiveness, migration, more chemosensitivity and reversal of EMT in HepG2 cells, by which Nanog plays crucial roles in influencing the malignant phenotype of HepG2 cells.
IntroductionHuman hepatocellular carcinoma (HCC) is considered as the third leading cause of cancer-related death worldwide (1-3). In recent years, although surgical treatment has greatly improved the survival rate of HCC patients, its prognosis and survival rate remain poor due to frequent intra-hepatic and extrahepatic metastases and dissemination (3,4). Consequently, further investigation of the underlying molecular mechanisms are vital to identify novel therapeutic interventions and to improve the prognosis for HCC.Nanog, a central transcription regulator required for maintaining the self-renewal capacity and pluripotent state of embryonic stem cells (ESCs) along with Oct4 and Sox2 (5-10), exhibits elevated expression in various types of tumor cells (11,12). Intensive studies indicate that Nanog also executes parallel functions as in ESCs, participating in tumorigenesis and promoting the progression of certain types of tumors, including pancreatic cancer, gastrointestinal tumors, breast cancer, head and neck squamous cell carcinomas and human HCC (13-16). In addition, our previous study was the first to demonstrate that Nanog is involved in the invasion, chemoresistance, clonogenicity, migration and metastasis of the cervical carcinoma HeLa cell line (17). Nevertheless, the precise role of Nanog in human HCC has not been fully explored.Epithelial-mesenchymal transition (EMT), which was initially identified as a characteristic of morphogenesis during embryogenesis, is a transdifferentiation ...